Trial · NCT06265051
Tirofiban After Successful MT Recanalization in AIS
NCT06265051, Phase 2, Phase 3, Completed, Xiang Luo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tirofiban After Successful MT Recanalization in AIS. Trials, record NCT06265051. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06265051
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tirofiban After Successful MT Recanalization in AIS
- NCT number
- NCT06265051
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 1,380 participants, actual
- Lead sponsor
- Xiang Luo
- Conditions
- Acute Ischemic Stroke, Vessel Occlusion
- Interventions
- Tirofiban, Saline placebo
- First posted
- 2024-02-20
- Last updated
- 2026-03-11
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients functionally independent (mRS score 0 to 2) at 90 days | 90 days after randomization | independent outcome at 90 days |
| Primary | Number of participants with symptomatic intracranial hemorrhage | within 48 hours of randomization | According to Heidelberg Bleeding Classification |
| Secondary | Modified ranking scale (mRS) | 90 days after randomization | A 0-6 scale running from perfect health without symptoms to death |
| Secondary | Proportion of patients non-disabled (mRS score 0 to 1) or return to pre-morbid mRS score at 90 days (for patients with mRS > 1) | 90 days after randomization | Excellent functional outcome |
| Secondary | Proportion of patients ambulatory or bodily needs-capable or better (mRS score 0 to 3) | 90 days after randomization | Ambulatory or bodily needs-capable or better |
| Secondary | Number of participants with improvement of neurological function | 36 hours (24-48 hours) after randomization | Proportion of patients with an NIHSS score of 0-1 or a reduction of ≥4 points from baseline at 36 hours (24-48 hours) of randomization |
| Secondary | Health-related quality of life, assessed with the European Quality Five Dimensions Five Level scale (EQ-5D-5L) | 90 days after randomization | Health-related quality of life |
| Secondary | All-cause mortality | 90 days after randomization | The ratio of total deaths from all causes to the research subjects at 90 days of randomization |
| Secondary | Proportion of intracranial hemorrhage of any type | within 48 hours of randomization | Proportion of intracranial hemorrhage of any type within 48 hours of randomization |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06265051
GET https://conductscience.org/api/trials/v1/NCT06265051/registered